A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03482011 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Mirikizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company